Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Completed 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell 1

Interventions

Rituximab 4ibrutinib 2fludarabine phosphate 2fludarabine 2blinatumomab 2Vorinostat 2Radiation 2Nivolumab 2Lenalidomide 2Gemcitabine 2Cytarabine 2Cyclophosphamide 2CT-P10 2umbralisib 1ublituximab 1tafasitamab 1polatuzumab vedotin 1pembrolizumab 1ofatumumab 1molibresib 1magrolimab 1iberdomide 1glofitamab 1entinostat 1cirmtuzumab 1carmustine, poliferprosan 20 drug combination 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Tacrolimus 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, B-Cell × glofitamab × Clear all
NCT06670105 2025-09-17

A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡